 | ||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
|
LumavitaLumavita is a specialty biopharmaceutical company located in Basel, Switzerland, and dedicated to the development of anti-infective drugs for women’s health. Lumavita’s portfolio consists of LMV-601, a first-in-class anti-viral compound (treatment of Human Papilloma Virus infections leading to cervix cancer) currently in Phase I, and LMV-602 (pentamycin), foreseen to cure vaginitis caused by both candida and trichomonas.
August 27, 2009 Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland June 18, 2009 Lumavita AG announces new funding March 24, 2009 Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of |
|
|
|
|||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG |
||||||||||||||||||||||||||||||
Olivier Valdenaire
Sven Lingjaerde